Utah Medical Products, Inc.
NASDAQ:UTMD · NASDAQ Global Select
+$1.10 today
Vol 0.02M · Avg 0.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
9.5%
avg 14.0%
ROIC
7.6%
avg 12.6%
ROA
9.2%
avg 12.8%
Analysis
ROE is currently the strongest return metric at 9.5% versus its period average of 14.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kevin L. Cornwell | Chairman, Chief Executive Officer, President & Secretary | $341,709.00 | — | 79 | $0.00 | <0.01% |
Brian L. Koopman | Principal Financial Officer, Accounting Manager & Controller | $170,709.00 | — | 56 | $782.00 | 0.02% |
Marcena H. Clawson | Vice President of Corporate Sales | — | — | — | — | — |
Mark L. Fox | Vice President of Marketing | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +4.6% | +9.1% (8yr)14 analysts |
| Revenue | N/A | N/A | -1.1% | +12.0% (8yr)14 analysts |
| Net Income | N/A | N/A | +5.2% | +9.9% (8yr)14 analysts |
| EBIT | N/A | N/A | +1.0% | +10.0% (8yr)14 analysts |
Analysis
Recent growth has been strongest in Net Income at +5.2% over three years. Forward estimates point to Revenue at +12.0% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Prenetics Global Limited
NASDAQ:PRE
$343.75M
OraSure Technologies, Inc.
NASDAQ:OSUR
$298.46M
Perspective Therapeutics, Inc.
AMEX:CATX
$232.14M
Profound Medical Corp.
NASDAQ:PROF
$205.76M
InfuSystem Holdings, Inc.
AMEX:INFU
$183.45M
KORU Medical Systems, Inc.
NASDAQ:KRMD
$180.75M
Coherus Oncology, Inc.
NASDAQ:CHRS
$173.45M
Protalix BioTherapeutics, Inc.
AMEX:PLX
$169.60M
Neuronetics, Inc.
NASDAQ:STIM
$85.21M
Nyxoah S.A.
NASDAQ:NYXH
$60.36M
Who manages UTMD?
Utah Medical Products, Inc. (UTMD) lists 4 active executives. The top listed executive is Kevin L. Cornwell, Chairman, Chief Executive Officer, President & Secretary.
Are UTMD insiders buying or selling?
Recent insider activity shows net selling of $15.83M.
Explore More
Continue the stock analysis
Jump to another research area for this company.